SEC Form DFiling only, no announcement found
InterAct Therapeutics, based in Dallas, TX, reported $250,000 sold in a private offering of debt, with the first sale on July 20, 2026, in a Form D filed with the SEC on July 21, 2026. The filing says 1 investor has already invested. The offering authorizes up to $2,000,000.
Legal name on the filing: InterAct Therapeutics, Inc..
| Amount sold | $250,000Basis: Form D total amount sold, as of the filing of July 21, 2026. Not the announced round size. |
|---|---|
| Total offering | $2,000,000The most the company may sell under this offering. Not money raised. |
| Remaining to be sold | $1,750,000 |
| Securities offered | Debt |
| Exemption claimed | Rule 506(b) |
| Date of first sale | July 20, 2026 |
| Investors already invested | 1 |
| Non-accredited investors | None |
| Minimum investment accepted | $0 |
| Part of a merger or acquisition | No |
| Industry group | Other Health Care |
| Principal place of business | Dallas, TX |
| Jurisdiction of incorporation | DELAWARE |
| Entity type | Corporation |
| Year of incorporation | 2025 |
| Revenue range | Decline to Disclose |
| SEC CIK | 2107143 |
Round name, valuation, lead investor and participants are not on a Form D, so they are not shown. They appear here only when a press or company announcement is matched to this deal.
| Name, as filed | Relationship | VC Beast profile |
|---|---|---|
| Daniel Hargrove | Executive Officer, DirectorMr. Hargrove is the CEO and a director of the Issuer. | None linked |
| Isaac Chan | DirectorDr. Chan is a director of the Issuer | None linked |
Form D lists the company's executive officers, directors and promoters. A director is often an investor's board representative, but the filing does not say who invested.
| Filed | Form | Amount sold | Total offering |
|---|---|---|---|
| Jul 21, 2026 | D (original) | $250,000 | $2,000,000 |
The latest filing states the current amount sold; an amendment replaces the figure before it.
Filing only, no announcement found. The only source for this deal is the company's own SEC filing, made under penalty of law. When a press or company announcement is matched to it, it is cited here with the round name it gives.
Amount sold is the filing's total amount sold; total offering is its authorized maximum. This page was built from filings received through September 29, 2026. Report an error on the corrections page.
Cite this deal
VC Beast, "InterAct Therapeutics: SEC Form D deal record", https://vcbeast.com/deals/interact-therapeutics-form-d-2026-07-20. Source: SEC EDGAR, accession 0002107143-26-000001.